Skip to content
Screener

iRadimed IRMD Q2 2026 earnings

Reported July 31, 2026 · Before market open

Revenue$20.5MBeat by $116.0K
EPS$0.46Beat by $0.02
Revenue estimate$20.4M
EPS estimate$0.44
“For the third quarter of 2026, we expect revenue of $23.0 million to $24.5 million and GAAP diluted earnings per share of $0.49 to $0.54 and non-GAAP diluted earnings per share of $0.54 to $0.59. We reaffirm our guidance for the full-year 2026, expecting to report revenue of $91.0 million to $96.0 million, and GAAP diluted earnings per share of $1.90 to $2.05 and non-GAAP diluted earnings per share of $2.09 to $2.24”
Roger Susi

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$20.5M+0.3%
Gross profit$15.2M-5.0%
Operating income$6.4M-5.8%
Net income$5.2M-9.6%
EPS (diluted)$0.41-8.9%

Balance sheet

See full
Cash & equivalents$59.1M+11.5%
Total equity$101.7M+7.9%
Total assets$115.0M+8.0%

Cash flow

See full
Operating cash flow$5.9M-23.3%
CapEx$185.0K-93.0%
Free cash flow$5.8M+12.6%

Valuation & ratios

Valuation

as of 06/30/26
See full
Market cap$1.22B+58.8%
P/E53×+15.8×
P/S14.1×+4.2×

Profitability

See full
Gross margin75.9%-1.1pp
Operating margin31.9%+1.2pp
Net margin26.7%+0.1pp
FCF margin29.1%+10.8pp

Returns & leverage

See full
Return on equity23.5%-0.2pp
Current ratio9.5×+0.7×

Segments

By product

See full
MRI Compatible Patient Vital Signs Monitoring Systems$6.7M—
MRI Compatible IV Infusion Pumps$6.4M—
Disposables$4.8M—
Services and other$1.1M—
Amortization of extended maintenance agreements$758.0K—

FAQ

When did iRadimed report Q2 2026 earnings?
iRadimed (IRMD) reported Q2 2026 earnings on July 31, 2026 before market open.
What were iRadimed's Q2 2026 revenue and EPS?
iRadimed reported revenue of $20.5M and eps of $0.46 for Q2 2026.
Did iRadimed beat estimates in Q2 2026?
Revenue beat the consensus estimate of $20.4M by $116.0K. EPS beat the consensus estimate of $0.44 by $0.02.
How did iRadimed's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.3% from $20.4M a year earlier and eps declined 6.1% from $0.49.
Where can I find iRadimed's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-051240) and the 10-Q periodic report (0001628280-26-051402) directly on SEC EDGAR. The filing index links above go to sec.gov.